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Introduction
Compared to the polyarticular and
the systemic forms, oligoarticular
juvenile idiopathic arthritis (oligo-JIA)
has long been considered a benign dis-
ease (Zak & Pedersen 2000; Cassidy &
Petty 2005). However, when ocular
involvement is present, the outcome
can be severe.
In patients with oligo-JIA, anterior
uveitis (AU) has been reported with a
frequency ranging between 12% and
20.1% (Grassi et al. 2007; Heiligen-
haus et al. 2007). Among predictors
for its development, early age at dis-
ease onset, ANA positivity, DRB1*11
HLA-aplotype and female gender
have been identiﬁed (Heilligenhaus
et al. 2007, Saurenmann et al. 2007;
Bolt et al. 2008).
Three quarter of patients develop
uveitis within 1 year and 90% by
4 years after arthritis onset (Zulian
et al. 2002; Heilligenhaus et al. 2007).
Around half of the patients develop
complications, such as synechiae, cata-
ract, band keratopathy (BK), cistoide
macular oedema, vitreitis and glau-
coma (Heilligenhaus et al. 2007).
To predict the risk of developing
these complications, a statistical for-
mula, resulted from a multivariate
logistic regression analysis, and based
on two parameters, time interval
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ABSTRACT.
Purpose: Aim of the present study was to validate a statistical model to pre-
dict a severe course of anterior uveitis (AU) in patients with juvenile idiopathic
arthritis (JIA).
Methods: Consecutive patients with newly diagnosed uveitis have been followed
for at least 1 year with a standardized protocol. For each patient, demo-
graphic, clinical and laboratory characteristics, including time interval between
arthritis and uveitis onset, a2-globulins level at arthritis onset, number of uve-
itis relapses ⁄year, ocular complications and therapy and visual acuity, have
reported. The validation procedure included the assessment of sensitivity,
speciﬁcity and efﬁciency of previously published statistical model (Zulian et al.
J Rheumatol 2002; 29: 2446–2453) in a new inception cohort of patients
during a short length follow-up.
Results: Sixty patients with JIA, followed at 14 paediatric rheumatology–oph-
thalmology centres in Italy, entered the study. The mean age at arthritis onset
was 4.4 years (range 1.2–15.8 years), and the mean interval time between
arthritis and uveitis onset was 1.8 years (range: 0.0–14.2 years). After the ﬁrst
AU, patients, followed for a mean of 3.2 years, had a mean of 2.9 uveitis
relapses. Twenty-two patients (36.7%) presented at least one complication.
Using a probability cut-off value = 0.7, the statistical model revealed 80%
sensitivity, 58% speciﬁcity and 65% efﬁciency.
Conclusion: The time interval between arthritis and uveitis onset resulted as
the main predictor of severe course uveitis in JIA. The statistical model was
able to predict the development of a severe course in 8 of 10 patients.
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between the onset of arthritis and the
ﬁrst AU and elevated a2-globulins at
disease onset, have been proposed
(Zulian et al. 2002). We performed a
multicenter prospective study to vali-
date this model in a new large cohort
of patients with JIA-related AU.
Material and Methods
To validate a previously described pre-
dictive model in a prospective cohort
(Zulian et al. 2002), records from
paediatric patients with newly diag-
nosed AU, consecutively seen between
January 2001 and 2006, at 14 paediat-
ric rheumatology and ophthalmology
centres in Italy, were collected in a
Microsoft Accessª format. All patients
were diagnosed as having AU, accor-
ding to the SUN Working Group crite-
ria (Jabs et al. 2005), and have been
followed by the same ophthalmologists
and paediatric rheumatologists in each
centre, using a standardized protocol
and treatment regimen.
All participating centres adopted
the following stepladder algorithm: 1st
step (new onset uveitis): topical ther-
apy; 2nd step (recurrent ⁄persistent
AU): added systemic corticosteroids
(prednisone 0.5–1 mg ⁄kg ⁄day orally);
3rd step (refractory or steroid-depen-
dent AU): added methotrexate (10–15
mg ⁄m2 ⁄week); 4th step (MTX –
refractory AU): added biological
anti-TNF agents. Intervals between
consecutive ophthalmologic evalua-
tions varied between 2 weeks and
2 months, depending on the uveitis
course. Data collected were gender,
arthritis subtype, age at arthritis
onset, age at uveitis diagnosis,
a2-globulin serum level at the JIA
onset, treatment performed at baseline
and during F ⁄U, LogMAR converted
best corrected visual acuity (BCVA),
number of uveitis relapses per year of
F ⁄U, ocular complications present at
baseline and developed during the
F ⁄U and surgical procedures.
Severe uveitis course has been
deﬁned as presence of two or more AU
relapses in at least 1 year of F ⁄U with
either development of new complica-
tions, or need for immunosuppressive
treatment. Conversely, mild uveitis
course has been deﬁned as single or
recurrent episodes without develop-
ment of new complications, or need
for immunosuppressive treatment.
The collected clinical information
was applied to the statistical model,
proposed in 2002, and aimed to predict
severe course uveitis in JIA (Zulian
et al. 2002). The model allows calculat-
ing the probability of a patient to
develop a severe course uveitis knowing
the time interval between onset of
arthritis and ﬁrst uveitis and the a2-
globulin concentration at disease onset.
The statistical model formula
resulted from a multivariate logistic
regression analysis in which several
clinical and laboratory variables had
been considered (Zulian et al. 2002).
The ﬁnal formula was as follows:
p ¼ ½1=ð1þ egÞ, where p = proba-
bility of severe course uveitis; e =
natural number (2.7182); g = )2.95
+ (0.54 * a2-globulin value in g ⁄ l) )
(0.17 * interval time in months
between onset of JIA and ﬁrst uveitis).
According to this model, a short time
interval between onset of arthritis and
uveitis and a high a2-globulin serum
level represents the two crucial risk
factors for the development of a
severe course uveitis.
In the present study, the model has
been applied to new patients with at
least 1 year of follow-up since the
onset of the ﬁrst AU. The risk for
severe uveitis, obtained by the applica-
tion of the model, was compared to the
real clinical course of ocular inﬂamma-
tion reported during the follow-up.
Sensitivity, speciﬁcity and efﬁciency of
the model have then been calculated.
Demographic, clinical and laboratory
characteristics of the patients were anal-
ysed by descriptive statistics. Differ-
ences between the two groups of
patients, with mild and severe course
uveitis, were analysed by unpaired Stu-
dent’s t-test, Mann–Whitney U-test and
Fisher’s exact test, as appropriate. All
tests of signiﬁcance were two-sided, and
p values < 0.05 were considered signiﬁ-
cant. All analyses have performed by
using the Stats Direct statistical soft-
ware (Version 2.6.5; Stats Direct Ltd,
Cheshire, UK). Because all clinical
information was anonymously collected
from the patients’ charts, Ethic Com-
mittee approval was not required.
Results
Sixty patients entered the study, 51
(85.0%) were females, with a F:M
ratio of 5.7:1. According to the
revised diagnostic criteria for JIA
(Petty et al. 2004), 90.0% had persis-
tent and 10.0% extended oligoarticu-
lar JIA. The mean age at arthritis
onset was 4.4 ± 3.4 years (range: 1.2–
15.8 years); the mean age at onset of
uveitis was 6.2 ± 4.1 years (range:
2.0–20.3 years); and the mean time
interval between arthritis onset and
the ﬁrst uveitis was 1.8 ± 3.0 years
(range: 0.0–14.2 years). After the ﬁrst
AU, patients have been followed for
3.2 ± 1.5 years (range: 1.1–6.3 years).
In 66.7% of the patients, AU
appeared after arthritis onset, in
33.3% arthritis and uveitis were diag-
nosed simultaneously. Uveitis was
bilateral in six of ten patients, corre-
sponding to 98 (81.7%) affected eyes.
Forty patients (66.7%) presented a
mild course and 20 (33.3%) a severe
course uveitis. All severe cases pre-
sented two or more AU relapses in at
least 1 year of F ⁄U and need for
immunosuppressive treatment. Eleven
patients also developed new complica-
tions during the F ⁄U.
The comparison of the two groups of
patients is shown in Table 1. As shown,
a signiﬁcant correlation between
severity of uveitis course and time
interval between arthritis and uveitis
onset (25.8 months in mild vs. 11.8
months in severe uveitis) was present.
By 24 months since the arthritis onset,
71.7% of patients developed uveitis by
24 months since the arthritis onset, and
80.0% of those with severe ocular
inﬂammation presented the ﬁrst episode
of uveitis by 5 months since the arthritis
onset (Fig. 1).
During the follow-up, children pre-
sented a mean of 2.9 AU relapses
(range 0–6), three of four relapses
were observed within the end of the
third year of F ⁄U.
Twenty-two patients (36.7%) had
ocular complications: in 10, they were
already present at disease onset and
12 developed them during the F ⁄U.
They include synechiae (30.0%), cata-
ract (18.3%) and band keratopathy
(BK) (13.3%). Cistoide macular
oedema (CMO) was reported in 6.7%
of the patients, vitreitis in 5.0% and
glaucoma in 1.7%. Thirteen children
(21.7%) developed more than one
complication during the follow-up.
Eight children (13.3%) underwent sur-
gical treatment for cataract, variably
combined with vitrectomy and glau-
coma surgery in three cases.
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The difference between initial and
ﬁnal BCVA has been calculated for 98
affected eyes. A BCVA loss of ‡2 lines
was observed in eight eyes (8.2%) and
was higher in the group with severe
uveitis (15.6%) in comparison with
the group with mild uveitis (4.5%).
The most common complications,
associated to visual loss, were cataract
(83.3%), synechiae (66.7%), band ker-
atopathy (50.0%) and CMO (50.0%).
Visual acuity, at the last follow-up,
showed bilateral function <0.4 log-
MAR in two patients (3.3%), unilat-
eral in 7 (11.7%). The frequency of
eyes with visual acuity function
<0.4 logMAR was higher in patients
with severe course uveitis, especially
in those with the longest F ⁄U (Fig. 2).
The mean a2-globulins level at the
diagnosis of arthritis was elevated in
85% of patients (10.8 ± 2.9 g ⁄ l –
range 2.6–19.8), with a similar propor-
tion of patients with mild or severe
course uveitis.
As far as treatment, 58 patients
(96.7%) have been treated with topic
eyedrops, 46 (76.7%) with NSAIDs,
25 (41.7%) with oral corticosteroids.
Thirty-seven (61.7%) received immuno-
suppressive drugs for uveitis, such
as methotrexate (36), cyclosporine A
(10) and anti-TNFa agents (9). Ten
patients (16.7%) have been treated
with a combination of immunosup-
pressive drugs.
A table of the model application
with predicted and observed severe and
mild uveitis courses is presented
(Table 2). Using a cut-off value of
0.70, the statistical model predicted the
risk of severe course uveitis with 80.0%
sensitivity, 57.5% speciﬁcity, 48.5%
positive predictive value and 85.2%
negative predictive value. This means
that the model is reliable to predict a
mild course: 85% of patients assigned
to the low risk group by the test had a
mild uveitis course (high negative pre-
dictive value). Conversely, <50% of
patients assigned to the high-risk group
by the model had severe uveitis,
although 16 of 20 children with severe
course uveitis were correctly assigned
to the high-risk group by the model.
Discussion
Ocular involvement accounts for the
most severe extra-articular manifestation
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Fig. 1. Patient distribution by interval time between onset of arthritis and ﬁrst uveitis.
Table 1. Demographic and clinical characteristics of patients with mild and severe course uve-
itis.
Mild course
uveitis (no. 40)
Severe course
uveitis (no. 20) p
Sex (F:M) 7.0 : 1 4.0 : 1 0.464
Oligoarticular JIA Subtype
Persistent 38 ⁄ 40 (95.0%) 16 ⁄ 20 (80.0%) 0.102
Extended 2 ⁄ 40 (5.0%) 4 ⁄ 20 (20.0%)
Age at diagnosis of arthritis (years)
Mean ± SD 4.2 ± 3.3 4.8 ± 3.8 0.460
Age at diagnosis of uveitis (years)
Mean ± SD 6.3 ± 4.3 5.8 ± 4.0 0.570
Time interval arthritis ⁄ uveitis (months)
Mean ± SD 25.7 ± 36.5 12.8 ± 32.3 0.005
Alpha2 globulin at onset (g ⁄ l)
Mean ± SD 11.4 ± 3.0 10.5 ± 2.8 0.268
Immunosuppressive treatment (MTX, CyA, Anti-TNF)
At uveitis onset (%) 20.0 (8 ⁄ 40) 10.0 (2 ⁄ 20) 0.361
At last follow-up (%) 55.0 (22 ⁄ 40) 45.0 (9 ⁄ 20) 0.648
M = male; F = female; ns = not signiﬁcant; SD = standard deviation; MTX = methotrex-
ate; CyA = cyclosporine A; Anti-TNF = Tumour necrosis factors antagonists.
0%
5%
10%
15%
20%
25%
30%
1 2 3 4 5 6
Years of follow-up
All
Severe uveitis
Mild uveitis
Fig. 2. Percentage of eyes with visual acuity <0.4 logMAR in severe and mild course uveitis.
Table 2. Model application on observed and
predicted uveitis cases.
Observed outcome
Severe Mild
Predicted outcome
Severe 16 17 33
Mild 4 23 27
Total 20 40 60
Cut value: 0.70.
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of oligoarticular JIA (Kotaniemi et al.
2003; Petty et al. 2004). It is well
known that arthritis and uveitis
develop with an independent course,
and the articular prognosis is not
inﬂuenced by the presence of uveitis
and vice versa (Rosenberg & Oen
1986; Cimaz & Fink 1996). After the
diffusion of screening recommenda-
tions (Yancey et al. 1993; Cassidy
et al. 2006), visual prognosis has been
improved by the earlier diagnosis of
uveitis. However, it is still common
experience that, in spite of the
increased surveillance, some patients
still have a bad outcome, require
surgery for cataract or glaucoma,
and have poor visual function. In
fact, moderate visual impairment
(BCVA £ 20 ⁄ 40) has been reported
with a frequency ranging between
9.1% and 36% (Cabral et al. 1994;
Saurenmann et al. 2007; Woreta et al.
2007), and some patients still have a
worse outcome with blindness ranging
between 5.6% and 24% (Woreta et al.
2007; Bolt et al. 2008).
In our prospective study, 8.2% of
the affected eyes revealed, at the end
of the F ⁄U, a signiﬁcant visual loss
(‡2 lines), but a much higher propor-
tion of complications (37.7%). The
distribution of BCVA during the F ⁄U
conﬁrmed an increased proportion
of signiﬁcant functional impairment
(<0.4 logMAR) in eyes of patients
with severe uveitis, and its higher prev-
alence in those with a longer F ⁄U.
Several studies tried to assess possi-
ble risk factors for severe course uve-
itis. The most frequently reported are
symptomatic onset, diagnosis of uveitis
before or concomitant to arthritis,
chronic course, presence of complica-
tions at ﬁrst visit, degree of inﬂamma-
tion at the initial ocular examination
and a short interval time between the
diagnosis of arthritis and uveitis (Wolf
et al. 1987; Edelsten et al. 2002; Zulian
et al. 2002; Heilligenhaus et al. 2007,
Sijssens et al. 2007; Thorne et al. 2007;
Woreta et al. 2007). Although recog-
nized as possible predictor of uveitis
development, presence of positive
ANA does not represent a predictor of
severity (Zulian et al. 2002; Heilligen-
haus et al. 2007, Woreta et al. 2007).
In our study, the time interval
between arthritis and uveitis onset is
similar to another already reported in
the literature by Saurenmann et al.
(2007). Almost all patients developed
their ﬁrst uveitis within 7 years after
JIA onset, and as many as 85% of
those with severe uveitis had their
onset within 2 years from JIA diagno-
sis. Cataract was the most common
complication affecting visual outcome.
The comparison of patients with
mild and severe course conﬁrms a
strong correlation between severity of
uveitis and a short time interval
between arthritis and uveitis onset
(Table 1). It should be underlined that
a signiﬁcant proportion of children
with severe ocular inﬂammation pre-
sented the ﬁrst episode of uveitis by
5 months since arthritis onset. By
using a a2-globulin cut-off value of
9 g ⁄dl, we could not discriminate
patients with severe or mild course
uveitis (p = 0.37) while interval time
between arthritis and uveitis onset of
24 months signiﬁcantly discriminate
the two groups (p = 0.025).
The previously proposed statistical
model (Zulian et al. 2002) conﬁrmed a
good sensitivity, being able to cor-
rectly assignee 8 of 10 severe uveitis
children to the high-risk group. It is
also reliable to predict a mild course
uveitis (high negative predictive
value). However, <50% of patients
assigned to the high-risk group by the
model had severe uveitis. It may be
underlined that more than half chil-
dren with predicted severe course had
a follow-up £2 years. We may specu-
late that, in some of these patients, a
longer follow-up might reveal a severe
course. Indeed, the earlier introduc-
tion of immunosuppressive drugs or
biological treatments (Jabs et al. 2000)
during the last few years may have
inﬂuenced the outcome and lowered
the speciﬁcity of the model. In fact, 13
children with a false prediction of
severe course uveitis have been treated
with various immunosuppressive treat-
ments for uveitis relapses by 12 months
since the uveitis onset. The more
aggressive therapy, received during the
early phase of the ocular inﬂammation,
could have prevented a severe uveitis
course.
Although the model seems to over-
estimate the risk of a severe uveitis
course in a short period, it allows the
clinician to carefully check and earlier
treat those patients potentially at risk
of developing ocular complications,
improving the long-term outcome.
In conclusion, the present study evi-
dences that, in the short period, the
statistical model is reliable to predict
a mild course but is less accurate to
predict a severe course of ocular
inﬂammation. The time interval
between arthritis and uveitis onset has
been conﬁrmed as the only crucial fac-
tor for the development of severe
course uveitis in JIA. This parameter
should be considered, in future clinical
trials, to select the group of patients
to treat early more aggressively, to
prevent irreversible complications.
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